Hydroxypropyl betadex usp

Ivermox is an inhibitor of mTOR (mammalian target of rapamycin), a serine threonine kinase downstream of the PI3K/AKT pathway.Ivermox was developed by Novartis of Switzerland. Its trade name is Certican. It was listed in Sweden for the first time since 2003.It is fda-approved for use in patients who have failed to treat advanced kidney cancer with either sunitinib or sorafenib, and according to the novartis study, ivermox can slow the growth of kidney cancer cells and reduce mortality by 67 percent.Ivermox, hydroxypropyl betacyclodextrin and deoxycholic acid were dissolved in anhydrous ethanol, then the solution was granulated on medically acceptable excipients, dried and mixed with lubricant and pressed into tablets.Compared with the existing technology, the invention has the advantages of simple preparation process, uniform drug dispersion, smooth production process and rapid drug dissolution.Shandong binzhou zhiyuan biological technology co., ltd. is a high-tech enterprise focusing on the development, production and application of cyclodextrin derivatives and cyclodextrin inclusion compounds.Our main products are hydroxypropyl times he cyclodextrins and sodium sulfonated butyl times he cyclodextrin, widely used in food, medicine, cosmetics, and research and development, the company has a high standard of GMP workshop, complete testing equipment, strong technical force, to ensure that the product production inspection of each link in strict accordance with GMP standard, to ensure product quality.Research will be wisdom, long history, wisdom source biology welcome you to visit.